Below is a comprehensive archive of press releases from MSF USA. Use the options in the boxes below to filter results based on your preferences.

Country/Region

January 23, 2015

New intellectual property "think tank" draft policy already showing alarming trend.

January 14, 2015

The Indian Patent Controller today rejected one of Gilead’s key patent applications, which covered the drug sofosbuvir, used to treat hepatitis C (HCV). The oral drug, which first received regulatory approval in the US in November 2013, and has been priced by Gilead at US$84,000 for a treatment course, or $1,000 per pill in the US, has caused a worldwide debate on the pricing of patented medicines. A study from Liverpool University showed that sofosbuvir could be produced for as little as $101 for a three-month treatment course.

September 26, 2014

As Indian prime minister Narendra Modi makes his first official visit to the US, MSF is urging the Indian government to resist US pressure to drop the use of public health safeguards in its intellectual property laws.

October 10, 2013

Outgoing International President MSF Dr. Unni Karunakara is taking to the road on a bicycle to travel 5000 kilometers in India to spark dialogue on health, health care, and humanitarianism.

October 04, 2012

MSF launched the Patent Opposition Database as part of the campaign to boost access to medicines in countries where patients can't afford the high drug prices some companies seek to preserve.  

March 27, 2012

On July 10, 2012, India's Supreme Court will hear the challenge to the country's patent law by Novartis, a case with enormous ramifications for the production of low-cost generic medications.

March 12, 2012

A landmark patent ruling in India could possibly set a precedent that allows patients in developing countries far greater access to essential medicines.

February 08, 2012

A new free trade agreement between the EU and India could severely impact access to affordable medicine in developing countries.

September 06, 2011

Novartis is lobbying India's Supreme Court to undo a key safeguard in Indian patent law, which would have a devastating impact on access to affordable medicines across the developing world.

June 21, 2011

NEW DELHI/BRUSSELS, June 22, 2011–At the United Nations High Level Meeting on HIV and AIDS in early June, India announced that it will not accept data exclusivity, a provision harmful to access to affordable medicines, as part of a free trade agreement (FTA) currently being negotiated with the European Union (EU).

Pages